Tamara Melck - NeonMind Biosciences Chief Officer
| NMDBFDelisted Stock | USD 0.50 0.00 0.00% |
Insider
Tamara Melck is Chief Officer of NeonMind Biosciences
| Phone | 866 811 8960 |
| Web | https://www.neonmindbiosciences.com |
NeonMind Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.8822) % which means that it has lost $1.8822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (37.2157) %, meaning that it generated substantial loss on money invested by shareholders. NeonMind Biosciences' management efficiency ratios could be used to measure how well NeonMind Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.NeonMind Biosciences has accumulated 450.01 K in total debt with debt to equity ratio (D/E) of 1.58, which is about average as compared to similar companies. NeonMind Biosciences has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist NeonMind Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, NeonMind Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NeonMind Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NeonMind to invest in growth at high rates of return. When we think about NeonMind Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Madison Crawford | ATAI Life Sciences | N/A | |
| MD MA | Mind Medicine | 44 | |
| Douglas Drysdale | Cybin Inc | 54 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Scott MD | Mind Medicine | 67 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Prof MD | Hookipa Pharma | 80 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Florian Brand | ATAI Life Sciences | 37 | |
| Aaron Bartlone | Cybin Inc | 57 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Julie ACA | GH Research PLC | 38 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Florian M | GH Research PLC | 55 | |
| Leah Gibson | Cybin Inc | N/A | |
| LLB LLB | Cybin Inc | 48 | |
| Alex Nivorozhkin | Cybin Inc | 64 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 |
NeonMind Biosciences Leadership Team
Elected by the shareholders, the NeonMind Biosciences' board of directors comprises two types of representatives: NeonMind Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeonMind. The board's role is to monitor NeonMind Biosciences' management team and ensure that shareholders' interests are well served. NeonMind Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeonMind Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, CEO CoFounder | ||
| Tamara Melck, Chief Officer | ||
| Robert Tessarolo, Pres Chairman | ||
| Ernie Ho, VP Devel | ||
| CPA CGA, Chief Officer | ||
| Trevor Millar, Advisor |
NeonMind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is NeonMind Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 | |||
| Operating Margin | 735.17 % | |||
| Current Valuation | 799.08 K | |||
| Shares Outstanding | 35.82 M | |||
| Price To Book | 12.19 X | |||
| Price To Sales | 18.10 X | |||
| Gross Profit | (84.45 K) | |||
| EBITDA | (6.65 M) | |||
| Net Income | (7.21 M) |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in NeonMind Pink Sheet
If you are still planning to invest in NeonMind Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeonMind Biosciences' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |